View Post

TAILORx 2019 Exploratory Analysis and SEER Data

In Clinical Studies News by Barbara Jacoby

Insights By: Terry P. Mamounas, MD From: onclive.com The results of the TAILORx trial that were presented in 2019 showed that clinical risk refines the results of the Oncotype DX recurrence score in terms of prognosis. In other words, in the multivariate analysis, clinical pathologic factors—clinical risk in other words—does correlate with outcome in addition to recurrence score. But what …

View Post

Researchers Report Positive Preliminary Data, Favorable Safety Update for Pelareorep in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Aislinn Antrim, Assistant Editor From: pharmacytimes.com The Safety Committee evaluating Onclytics Biotech Inc’s pelareorep has found no safety concerns after evaluating the first 3 cohorts.1 Early findings from the AWARE-1 trial investigating pelareorep for early-stage breast cancer have found that T cell clonality may support the development of a biomarker for the disease, according to a press release.2 More …

View Post

Novel Immunotherapy Strategy Demonstrates Favorable Toxicity in Early-Stage Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Danielle Ternyila From: targetedonc.com Patients with early-stage breast cancer who received pelareorep demonstrated consistent data with safety run-in data and had a favorable toxicity profile, according to an cohort analysis from the window-of-opportunity study, AWARE-1 (NCT04102618).1 Safety parameters were evaluated by a committee of investigators from patients who participated in the safety run-in portion of the trial. The committee …

View Post

Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Agendia From: PR Newswire Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that BMC Cancer published results from the IMPACt trial. The study measured changes in both treatment decisions and physician confidence when using the MammaPrint® and BluePrint® assays to support medical management for patients with early stage breast cancer. Because breast cancer is …

View Post

Tiny Seeds, Big Promise: Breakthrough Procedure Helping Breast Cancer Patients In Just One Treatment

In In The News by Barbara Jacoby

From: newyork.cbslocal.com There’s been a medical breakthrough for women with early stage breast cancer. Instead of having to go through months of chemo and radiation, doctors are using just one treatment that’s much easier on patients, Dr. Max Gomez reports. Connie Frameli has had breast cancer twice, so when the disease came back last year, she dreaded going through radiation …

View Post

AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

In Clinical Studies News by Barbara Jacoby

Source: ACCESSWIRE From: yahoo.com AIM ImmunoTech Inc., (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) – announced progress toward the opening of Roswell Park Comprehensive Cancer Center’s Phase 1 clinical study of chemokine modulation plus neoadjuvant chemotherapy in …

View Post

PreludeDx Present Results from PREDICT Study at ASBrS Annual Meeting

In Clinical Studies News by Barbara Jacoby

Source: Prelude Corporation From: prnewswire.com Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, presented interim results from its large PREDICT study during a poster presentation (Abstract ID: 581643), titled “Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy (RT) Benefit in Patients with DCIS”, …

View Post

Denosumab Improves Bone Health, Disease-Free Survival in Hormone Receptor–Positive Breast Cancer

In In The News by Barbara Jacoby

By: Jaime Rosenberg From: ajmc.com In postmenopausal women with hormone receptor–positive, early-stage breast cancer receiving treatment with aromatase inhibitor therapy, the addition of denosumab results in a significant reduction in clinical fractures, according to results of a new study, which also found that the treatment yielded benefits for disease-free survival. While aromatase inhibitor therapy is the standard of care for …

View Post

Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour eFrom: onclive.com The collective results of the MINDACT and TAILORx trials provided a better directive in terms of whether or not to give endocrine therapy alone or in combination with chemotherapy for patients with node-negative, early-stage hormone receptor (HR)–positive, HER2-negative breast cancer, said Mariana Chavez Mac Gregor, MD, MSc. “In patients who have early-stage HR-positive, HER2-negative disease, …

View Post

Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

In In The News by Barbara Jacoby

From: businesswire.com Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update Biotheranostics, Inc. announces recommendations for Breast Cancer Index …